![](/img/cover-not-exists.png)
Brentuximab vedotin and anti‐PD1 treatment optimize survival in chemo‐refractory Hodgkin lymphoma patients: real‐world data
Sakellari, I., Gavriilaki, E., Iskas, M., Bousiou, Z., Chatziioannidis, A., Batsis, I., Mallouri, D., Constantinous, V., Stavroyianni, N., Syrigou, A., Marvaki, A., Pilavaki, M., Papaemmanouel, S., AnLanguage:
english
Journal:
Hematological Oncology
DOI:
10.1002/hon.2645
Date:
June, 2019
File:
PDF, 416 KB
english, 2019